Funding Cuts Threaten Progress on Antimicrobial Resistance: What You Need to Know
"Proposed budget cuts in the U.S. could undermine efforts to combat antimicrobial resistance, endangering patients and global health security. Here's a breakdown of the potential impact and why it matters."
Antimicrobial resistance (AMR) is a serious and growing threat to public health, endangering the lives of patients and undermining the safety of essential medical procedures. Complex medical interventions rely on effective antimicrobial drugs to manage infections, and the rise of AMR jeopardizes these advances. Over the past few years, global leaders have recognized the urgency of this issue and started to make real progress.
However, proposed budget cuts by the Trump administration pose a significant risk, potentially undoing much of the progress made and putting patients in harm's way. The Centers for Disease Control and Prevention (CDC) estimates that in the United States alone, at least 2 million people acquire antibiotic-resistant infections each year, resulting in at least 23,000 deaths. The economic impact is also substantial, costing the U.S. health system more than $20 billion annually.
Globally, the situation is even more dire. Approximately 700,000 deaths each year are attributed to AMR. If current trends continue, it is estimated that AMR will cause a cumulative total of 350 million deaths by 2050, with multidrug-resistant tuberculosis accounting for a significant portion of these fatalities.
A Measurable Global Threat
The CDC tracks antimicrobial resistance in the United States and abroad through multiple data sources and systems. WHO describes its AMR Data Portal as a central resource for monitoring human-health indicators and warns that insufficiently coordinated global action could lead to a post-antibiotic era. WHO reports that approximately 1 in 6 laboratory-confirmed bacterial infections worldwide were resistant to antibiotics in 2023.
Detection Has Practical Limits
Culture-based approaches remain important for detecting antimicrobial resistance, but current methods have limitations in sensitivity, turnaround time, and their ability to identify all potential resistance genes. Classic antimicrobial susceptibility testing methods can be accurate while also being time-consuming and relatively expensive. The literature therefore emphasizes written and physical standards for resistance-gene detection by whole-genome sequencing and rapid, accurate diagnostics to support antimicrobial stewardship.
A Long-Developing Problem
The development of antimicrobial resistance can be understood as a long-running process shaped by changing pathogens, treatments, and patterns of antimicrobial use. Foundational discoveries and later medical advances created powerful tools against infection, but resistance has continued to evolve. A fuller historical account would require sources addressing specific discoveries, milestones, and dates.
How Would Funding Cuts Impact the Fight Against AMR?
Recognizing the severity of the AMR threat, leaders from the United States and other nations have been working to develop comprehensive strategies to combat it. The Group of Twenty (G20), including President Trump, released a declaration acknowledging AMR as a major threat to public health and economic stability. The declaration included pledges to promote responsible antibiotic use, enhance infection prevention, and support research and development of new antibiotics.
- Slowing Down Detection and Response: Funding cuts would impact the CDC and state/local health departments. This would mean less rapid detection of outbreaks.
- Weakening Laboratory Capacity: Less funding reduces state-of-the-art laboratory capacity through the CDC's regional network, limiting screening and prevention.
- Hindering Research: Cuts to the National Institute of Allergy and Infectious Diseases (NIAID) would affect the understanding of resistance development and the creation of new diagnostic tests, vaccines, and treatments.
Research Is Expanding
Current research on antimicrobial resistance spans pathogen biology, diagnostics, treatment strategies, and prevention. Reviews can help organize evidence across these areas, but their conclusions may depend on the studies and settings included. Without subsection-specific sources here, the latest findings should be interpreted cautiously rather than summarized as settled evidence.
Progress Does Not Eliminate Failure
Reviews identify antibiotic misuse and overuse in human and animal sectors as drivers of resistant microorganisms and multidrug-resistant pathogens. The continuing search for new antibiotics remains urgent, while one review reports a persistent lack of pharmaceutical-industry investment in new antibiotic research. Treatment failure also cannot always be attributed to genetically encoded resistance, meaning that antimicrobial resistance is not the only explanation when therapies fail.
Evidence Requires Context
Comparisons of antimicrobial-resistance interventions should account for differences in pathogens, healthcare settings, available diagnostics, and treatment access. Results from one setting may not transfer directly to another. In the absence of subsection-specific comparative sources, broad conclusions about which approach is superior would be premature.
The Imperative to Reaffirm Our Commitment
Given the gravity of the AMR threat and the United States' historical role as a leader in global progress, it is crucial to reaffirm our commitment to research and public health initiatives aimed at combating this challenge. By maintaining and increasing funding for AMR programs, we can protect patient safety, strengthen global health security, and ensure that future generations are not burdened by the devastating consequences of unchecked antimicrobial resistance.
Prescribing Is Also a Human Decision
A 2026 study reports that clinicians’ cognitive biases and perceptions of resistance risk can shape antimicrobial prescribing in real-world practice. These influences may contribute to unnecessary broad-spectrum antibiotic use and increased antimicrobial pressure. A systematic synthesis of expert opinion separately examined policies considered effective for tackling bacterial resistance worldwide, underscoring the importance of policy-informed responses alongside clinical judgment.
Forecasting the Next Phase
The GBD 2021 Antimicrobial Resistance Collaborators estimated deaths associated with and attributable to bacterial AMR from 1990 to 2021 and produced forecasts through 2050. Their analysis covers 204 countries and territories and draws on hospital discharge records, microbiology data, and mortality surveillance. The accompanying discussion also considers how COVID-19 may affect assessment of the global AMR burden, showing why future projections require careful interpretation.
A System-Wide Challenge
Antimicrobial resistance affects more than the choice of an individual drug or the treatment of a single infection. Its broader context includes prevention, diagnostics, prescribing, surveillance, access, and coordination across health systems. Because no subsection-specific sources were provided here, these systemic connections should be treated as a general framework rather than as quantified findings.
Resistance Has Human Consequences
A 2025 review describes antimicrobial-resistant pathogens as a global health threat driven by indiscriminate antimicrobial use. It examines molecular and ecological mechanisms of resistance, along with global containment efforts and actionable mitigation strategies. The review also notes that resistance can be acquired through genes carried on mobile elements, helping explain how resistant traits may spread.